Metsera, Inc. Announces Progress on Clinical Pipeline and Financial Results
### Pipeline Developments and Future Milestones
Metsera, Inc. is on track with its clinical advancements, particularly focusing on its obesity and metabolic disease treatments. The company plans to release data from the VESPER-1 and interim VESPER-3 studies for its lead drug MET-097i in September 2025, with a global Phase 3 program initiation anticipated for late 2025. MET-097i, a subcutaneously injectable GLP-1 receptor agonist, has shown promising results in weight loss and tolerability during clinical trials. The ongoing VESPER trials aim to solidify MET-097i’s profile and facilitate a swift transition into Phase 3 testing.
### Highlights on MET-233i and Co-Administration Studies
MET-233i, another promising candidate from Metsera, has achieved notable Phase 1 results, including a weight loss of 8.4% over five weeks and a favorable half-life of 19 days. This monthly injectable amylin analog is being evaluated both as a standalone treatment and in combination with MET-097i. Interim data on the co-administration of these two drugs is expected by the end of 2025 or early 2026, which could pave the way for a groundbreaking combination therapy in weight management.
### Updates on Oral Peptide Programs
Metsera is also advancing its oral peptide programs, with MET-097o and MET-224o, both long-acting GLP-1 receptor agonists targeting obesity. Initial four-week data from the selected lead candidate is expected by late 2025. This expansion of their portfolio reflects the company’s commitment to diversifying treatment options for weight management.
### Financial Overview for Q2 2025
As of June 30, 2025, Metsera reported $530.9 million in cash and cash equivalents, a substantial increase from $352.4 million at the end of 2024. This financial position is expected to sustain the company’s operational needs through 2027. Research and development expenses surged to $60.5 million for the second quarter of 2025, compared to $20.9 million the previous year, attributed to ongoing clinical trials and personnel costs.
### General and Administrative Expenses
Metsera’s general and administrative expenses also rose, totaling $11.5 million in Q2 2025, up from $5.6 million in Q2 2024. This increase primarily reflects higher personnel costs and professional fees associated with operating as a public entity.
### Net Loss and Operational Insights
The company recorded a net loss of $68.7 million for the second quarter of 2025, a significant increase from $26.7 million in the same period last year. This loss is largely due to elevated R&D and G&A expenses, alongside a change in fair value of contingent consideration. The total cash used in operations for the first six months of 2025 stood at $113.3 million.
### About Metsera
Metsera, founded in 2022 and based in New York City, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for obesity and metabolic disorders. The company is working on a diverse range of therapies, including oral and injectable options, aimed at addressing various therapeutic targets in the evolving landscape of weight management therapies.
### Forward-Looking Statements
This announcement contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could lead to actual results differing from expectations. Metsera intends to provide updates on its progress but does not commit to any obligation outside of legal requirements.
